ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1588

Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia

Julia Tan1, J. Antonio Avina-Zubieta2, Alyssa Dominique3, Hamid Tavakoli4 and Teresa A Simon3, 1Medicine, University of British Columbia, Vancouver, BC, Canada, 2Division of Rheumatology, Department of Medicine, University of British Columbia, Vancouver, BC, Canada, 3Bristol-Myers Squibb, Princeton, NJ, 4Arthritis Research Canada, Vancouver, BC, Canada

Meeting: 2018 ACR/ARHP Annual Meeting

Keywords: Malignancy, population studies, psoriasis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, October 22, 2018

Title: Spondyloarthritis Including Psoriatic Arthritis – Clinical Poster II: Clinical/Epidemiology Studies

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Psoriasis (PsO) is a relapsing chronic autoimmune disease of the skin. Up to one-third of patients (pts) also develop inflammatory arthritis, known as psoriatic arthritis (PsA). PsO/PsA, like other forms of chronic inflammatory arthritis, are often associated with complications such as cardiovascular disease and infections. However, data on the risk of cancer in pts with PsO/PsA at population level are limited.

Methods: We created a population-based matched retrospective cohort of PsO/PsA pts diagnosed between 1 January 1997 and 31 December 2012 using administrative health data from British Columbia, Canada. We identified all incident cases of PsO/PsA and an equal number of controls matched on sex, age and calendar year. PsO/PsA cases met ≥1 of the following: 1 diagnostic code for PsO/PsA by a rheumatologist/dermatologist; ≥2 diagnostic codes for PsO/PsA, ≥2 months apart in a 2-year period by a non-rheumatologist/dermatologist; or ≥1 hospitalization with diagnostic code for PsO/PsA. We evaluated incident cancers during follow-up from the Cancer Registry in both cohorts. Adjusted risk of cancers was estimated using a generalized estimating equation extension of multivariate Poisson regression models.

Results: We identified 81,568 incident cases of PsO/PsA (mean age 48.5 years [SD=17.8], 51.5% female). Individuals with PsO/PsA were at significantly higher risk of being diagnosed with 8/41 types of cancer examined, including eye and orbit (4 fold), female genital (3 fold), non-melanoma skin (2 fold), prostate (males; 1.1 fold) (Table). Incidence of rectum and colon cancer was lower among PsO/PsA pts relative to the non-PsO/PsA cohort (Table)

Conclusion: This general population-based study demonstrates that pts with PsO/PsA have an increased risk of several types of cancer, and a decreased risk of rectum and colon cancer. This association highlights the need to further explore potential risk factors and pathways that contribute to these complications.

Outcome

PsO/PsA events

Non-PsO/PsA events

PsO/PsA follow-up (PY)

Non-PsO/PsA follow-up (PY)

PsO/PsA IR (per 100,000 PY)

Non-PsO/PsA IR (per 100,000 PY)

IRR
(95% CI)

Eye and orbit

13

<5

623,843.5

<5

2.08

–

4.25
(1.21, 14.91)

Female genital other than cervix uteri, corpus uteri and ovary

55

21

623,625.8

611,542.1

8.81

3.43

2.57
(1.55, 4.25)

Other urinary

31

16

623,818.6

611,585.4

4.97

2.62

1.90
(1.04, 3.47)

Non-melanoma skin

401

217

621,233.8

610,223.9

64.54

35.56

1.82
(1.54, 2.14)

Lung

705

589

622,877.2

610,834.8

113.18

96.42

1.17
(1.05, 1.31)

Prostate

760

664

620,065.8

608,124.9

122.57

109.19

1.12
(1.01, 1.25)

Melanoma

218

200

622,791

610,672.1

35.0037

32.7508

1.07

Colon

286

332

622,845.1

610,410.5

45.91

54.39

0.84
(0.72, 0.99)

Rectum

157

194

623,196.9

610,811.7

25.19

31.76

0.79
(0.64, 0.98)

IRR=incidence rate ratio; PY=patient years


Disclosure: J. Tan, None; J. A. Avina-Zubieta, Bristol-Myers Squibb, 2; A. Dominique, Bristol-Myers Squibb, 3; H. Tavakoli, None; T. A. Simon, Bristol-Myers Squibb, 3.

To cite this abstract in AMA style:

Tan J, Avina-Zubieta JA, Dominique A, Tavakoli H, Simon TA. Risk of Cancer in Patients with Psoriasis/Psoriatic Arthritis: A Population-Based Study in the Province of British Columbia [abstract]. Arthritis Rheumatol. 2018; 70 (suppl 9). https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2018 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/risk-of-cancer-in-patients-with-psoriasis-psoriatic-arthritis-a-population-based-study-in-the-province-of-british-columbia/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology